Trial Profile
PHASE II STUDY OF PACLITAXEL (TAXOL), INTRAPERITONEAL CISPLATIN AND IV AVASTIN FOLLOWED BY AVASTIN CONSOLIDATION FOR ADVANCED OVARIAN AND PERITONEAL CARCINOMA OR FALLOPIAN TUBE CANCER
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Paclitaxel
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 29 May 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jul 2015 to 1 May 2016.
- 29 May 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Jul 2015 to 1 May 2016.
- 20 May 2014 Planned End Date changed from 1 Jul 2012 to 1 Jul 2015, as per ClinicalTrials.gov record.